Literature DB >> 7575124

Retroperitoneal sarcomas and their management.

C P Karakousis1, R Gerstenbluth, K Kontzoglou, D L Driscoll.   

Abstract

BACKGROUND: Retroperitoneal sarcomas historically have presented difficulties in their management due to a high rate of unresectability.
OBJECTIVE: To determine prognostic parameters, resectability, and survival of these patients in a more recent period.
DESIGN: Retrospective review, with a mean follow-up of 47 months.
SETTING: Tertiary care cancer institute. PATIENTS: The charts of 90 consecutive patients with retroperitoneal sarcomas treated in the period from 1977 to 1995. No patient referred with a localized retroperitoneal sarcoma was excluded from this review.
RESULTS: The resectability rate was 100% for the primary tumors (n = 57) and 88% for the tumors initially presenting as local recurrence (n = 33). The 5-year survival rate was 63% (66% for patients with primary tumors and 57% for those with local recurrence). The 10-year survival rate was 46% (57% for patients with primary tumors and 26% for those referred with local recurrence). The local recurrence rate was 25% for primary tumors and 39% for tumors initially presented as local recurrence (overall rate, 30%); it was 56% after local excision and 16% after wide or radical resection (P < .001). The 5- and 10-year survival rates were 72% and 61%, respectively, for those with wide resection and 55% and 23%, respectively, for those with local excision (P = .01).
CONCLUSIONS: With modern surgical techniques, the overall resectability rate of retroperitoneal sarcomas is 96%. The ensuing survival, affected significantly by the histologic grade, approaches that for the extremity sarcomas.

Entities:  

Mesh:

Year:  1995        PMID: 7575124     DOI: 10.1001/archsurg.1995.01430100082016

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  11 in total

1.  [Retroperitoneal leiomyosarcoma. A rare differential diagnosis of an adrenal tumor].

Authors:  J Hodzic; K Golka; K Möhring; G Riedasch
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

2.  Major vascular resection and prosthetic replacement for retroperitoneal tumors.

Authors:  Philipp Fueglistaler; Lorenz Gurke; Peter Stierli; Tamim Obeid; Christoph Koella; Daniel Oertli; Christoph Kettelhack
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Long-term outcome after multivisceral and tumor/vascular resection in patients with soft tissue sarcoma.

Authors:  P Vogel; U Bolder; M N Scherer; H-J Schlitt; K-W Jauch
Journal:  Langenbecks Arch Surg       Date:  2008-08-12       Impact factor: 3.445

Review 4.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.

Authors:  J J Lewis; D Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

5.  Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience.

Authors:  Imran Hassan; Saung Z Park; John H Donohue; David M Nagorney; Paul A Kay; Antonio G Nasciemento; Cathy D Schleck; Duane M Ilstrup
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

6.  Retroperitoneal sarcomas.

Authors:  Isaac R Francis; Richard H Cohan; Datla G K Varma; Vernon K Sondak
Journal:  Cancer Imaging       Date:  2005-08-23       Impact factor: 3.909

7.  Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery.

Authors:  Fuminari Uehara; Yukihiko Hiroshima; Shinji Miwa; Yasunori Tome; Shuya Yano; Mako Yamamoto; Yasunori Matsumoto; Hiroki Maehara; Kazuhiro Tanaka; Michael Bouvet; Fuminori Kanaya; Robert M Hoffman
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

8.  The value of surgery for retroperitoneal sarcoma.

Authors:  Sepideh Gholami; Charlotte D Jacobs; Daniel S Kapp; Layla M Parast; Jeffrey A Norton
Journal:  Sarcoma       Date:  2009-10-08

9.  Retroperitoneal sarcoma with infected necrosis: an unfavourable prognostic factor.

Authors:  A J Spillane; J M Thomas
Journal:  Sarcoma       Date:  1998

10.  Recent progress in the management of retroperitoneal sarcoma.

Authors:  R Cheifetz; C N Catton; R Kandel; B O'Sullivan; J Couture; C J Swallow
Journal:  Sarcoma       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.